AzTrials
AzTrials

Coronary Artery Bypass GraftingCCSRNCT02400125

China Cardiovascular Surgery Registry

An observational study of Coronary Artery Bypass Grafting and Surgical Treatment for Heart Valve Diseases, run by China National Center for Cardiovascular Diseases at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

China Cardiovascular Surgery Registry (CCSR) Study is a national database for coronary artery bypass grafting (CABG) and valve surgery performed in 87 hospitals with cardiovascular surgery volume > 100 per year. Read more about this study

Who is it for?
Any age
How many people
90,000 participants
Where
1 siteChina
Study dates
Mar 2013to Dec 2017
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: patients underwent isolated or combined coronary artery bypass grafting and/or surgical treatment for heart valve diseases

Who may be able to join

  • patients underwent isolated or combined coronary artery bypass grafting and/or surgical treatment for heart valve diseases

Who cannot join

  • none

Trial locations and contacts

1 site in 1 country.

Zhe Zheng, PhD, MD contact

+861088396356

zhengzhe@fuwai.com

China1 site, 1 recruiting
  • National Center for Cardiovascular Diseases, Fuwai Hospital

    Beijing, Beijing Municipality, 100037

    Zhe Zheng, MD, Phd, +861088396356, zhengzhe@fuwai.com

    Chenfei Rao, MD, +8618810488801, raochenfeifuwai@126.com

    Recruiting

Other trials in China

About this study

China Cardiovascular Surgery Registry (CCSR) Study is a national database for coronary artery bypass grafting (CABG) and valve surgery performed in 87 hospitals with cardiovascular surgery volume > 100 per year. The aims of CCSR Study are: (i) report the characteristics of patient, the quality and evolvement of CABG and valve procedures in China, (ii) build and valid surgical risk assessment tools for Chinese population, (iii) provide databases for clinical studies, and quality improvement initiatives.

Read the detailed description

The volume of cardiac surgery in China is increasing rapidly at a rate of approximately 10% annually, and has approached 207,881 at the year of 2013. Coronary artery bypass grafting (CABG) and valve procedures account for 41% of all. With the aging population, rising prevalence of cardiovascular diseases, and rapid economic development in China, the volume of cardiac procedures will continuously rise for years. In light of the burgeoning volume of cardiac procedures, considering the imbalance of economic development among regions, and the lack of standardized surgeon training system, critical concern with regards to the quality of cardiac surgery has been raised.

Under this circumstance, national registry to continuously collect patient-by-patient data for cardiovascular surgery is critically important to (i) report the characteristics of patient, the quality and evolvement of procedures, (ii) build and valid surgical risk assessment tools, (iii) provide databases for clinical studies, and quality improvement initiatives, (iv) promote international exchanges and cooperation. Following the example of national cardiac procedure databases, such as The Society of Thoracic Surgeons (STS) National Database and The European Association for Cardio-Thoracic Surgery (EACTS) Database, Fuwai Hospital, as one of the largest cardiac surgical care and research centers in China, leveraged an initiative to start the first multicenter cardiac surgery registry in Chinese mainland at 2004. The investigators started with 32 participating sites and registered CABG surgery during the first 2 years. From 2007, the investigators have included valve surgery as well. By the end of 2012, 66 coordinating sites have participated into this voluntary database continuously or intermittently, enrolled 61,558 surgery data. This database has become the most representative data source for adult cardiac surgery in China. This registry has (i) reported the performance and quality of adult cardiac surgery in China, shown that the observed and risk-adjusted in-hospital mortality rate of isolated CABG in China is 2.2% and 1.9% respectively, and identified certain variation among regions and sites, (ii) released an in-hospital mortality risk prediction system for CABG named SinoSCORE, which suit Chinese population better, (iii) worked with EACTS and merged both databases together for the 4th Adult Cardiac Surgical Database Report, (iv) acted as one platform and data source for clinical studies, published 14 papers in international indexed journals.

In order to extend the volume of participating sites, and build a representative database for the performance, in-hospital as well as 1-year outcomes of CABG and/or valve surgery in large cardiac surgery centers in China, at the year of 2013, China National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital leveraged The China Cardiovascular Surgery Registry (CCSR) network to push the CCSR Study forward. The CCSR Study established a network of 90 participating sites with cardiovascular surgery volume > 100 per year, and capability of performing CABG and/or valve surgery. The participating sites are required to consecutively and routinely submit CABG and valve surgery data regarding patients' personal information, risk factors, surgery performance, in-hospital outcomes and prescription drugs, through a web-based and paperless data collection system. The investigators also encourage all sites to interview patients at 1-month and 1-year after index procedure for mid-term outcomes and medications after discharge. The investigators conduct routine remote and on-site monitoring and auditing to ensure integrity and accuracy of data. Ethics Committee of Fuwai Hospital approved the study design and audits the conducting yearly.

For in-hospital data collection, CCSR established 11 modules (patient basic information, preoperative risks, cardiovascular presentation, cardiac examination, general information on operation, CABG, valve surgery, other surgeries, post-operative complications, pre-operative medication and medical order at discharge), 416 items, among which 157 items are core dataset, 259 are extended dataset. The core dataset is a mandatory set of variables believed to be necessary for accurate representation of clinical practice, risk model development, and analysis. The extended dataset includes less critical but still important fields that are strongly encouraged to be collected but are not mandatory for submitting. The creation of custom fields is permissible so that sites can collect specific information that is desired by themselves.

The investigators adapted Clinical Data Interchange Standards Consortium (CDISC) Standard for data collection and merging among international databases. The investigators established input items comparable to those of the STS National Database, the common terminologies and the definitions from STS National Database was adopted as well.

Coordinators are requested to consecutively register 5 variables regarding basic information of patients undergoing isolated or combined CABG and/or valve surgery in their hospital in 3 days after the surgery. The basic information includes name, sex, date of birth, type of surgery and ID number. The investigators request the coordinators to submit the complete in-hospital data within 28 days after the surgery. The investigators also developed a standard data interface for all in-hospital data elements. If the quality of participating sites' exported data from Hospital Information System meets the safety and quality criteria, it is also acceptable of these sites to export and import in-hospital data automatically instead of manual submitting.

The investigators encourage all participating sites to invite patients to join the prospective follow-up cohort and interview patients after discharge, but the follow-up interview is optional. Coordinators from participating sites interview the patients who have signed the informed consent during their index hospitalization and 1-month, 1-year after the index cardiac surgery face to face and by telephone. The data include major cardiovascular and cerebral outcomes, readmission, and self-administration.

In order to ensure the follow-up data authenticity, with the permission of patients and participating sites, NCC interviews patients at 3-month after their cardiac surgery using the same questionnaire.

Data variables have been added for internal quality and integrity checks. If any component of the required mandatory data elements are missing, or any of the validation roles of logic aren't meet, the data will be automatically rejected. In order to audit the accuracy of in-hospital data, the investigators randomly select 10-20% of each participating sites' in-hospital data, and require the coordinators to scan the coordinating medical record, and transferred to NCC using encryption flash drive. 2 physicians from NCC abstract all medical record data independently, and compare the data between NCC data abstraction and coordinators' database. The accuracy report of each sites are fed back to each participating site yearly. The on-site auditing are conducted once a year for each site. The main aim of on-site auditing is to ensure the consecutiveness of data registry. The investigators randomly select a period of time to check original record of surgery, and abstract data regarding patient ID and in-hospital outcomes. Any mismatch of auditing data with submitting data will be reported to NCC and participating sites.

Keywords
Patient Registry, Coronary Artery Bypass, Cardiac Valve Annuloplasty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02400125
Study groupRoleWhat they receive
1Patients underwent isolated or combined coronary artery bypass grafting surgery
2Patients underwent isolate or combined surgical treatment for heart valve disease

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. composite of post-operative all-cause mortality and major complications

    composite of death of any cause, reoperation, myocardial infarction, stroke, renal failure, pulmonary embolism, atrial fibrillation during the postoperative hospitalization

    Measured: participants will be followed for the duration of hospital stay after the index cardiac operation, an expected average of 2 weeks

Secondary outcomes (4)
  1. major adverse cardiac events

    composite of major adverse cardiac events (MACE) including death, myocardial infarction and/or revascularization

    Measured: 30 days

  2. major adverse cardiac events

    composite of major adverse cardiac events (MACE) including death, myocardial infarction and/or revascularization

    Measured: 1 year

  3. readmission

    composite of major adverse cardiac events (MACE) including death, myocardial infarction and/or revascularization

    Measured: 30 days

  4. readmission

    composite of major adverse cardiac events (MACE) including death, myocardial infarction and/or revascularization

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2015 (estimated)
  2. Study startMar 2013
  3. Primary completionDec 2015 (estimated)
  4. Study completionDec 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
90,000 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT02400125
Sponsor's protocol ID
MOST-2011BAI11B21
Other IDs
MOST-2011BAI11B02
Acronym
CCSR
Status last verified
Dec 2015
First submitted
22 Mar 2015
Last updated
16 Dec 2015
Results posted
No
Data monitoring committee
Yes

Publications

  • Deming Zhu CL, Feilong Hei. White Paper On 2013 China Cardiar Surgery And Extracorporeal Circulation Data. Chinese Journal of Extracorporeal Circulation 2014; 2014(3): 129-31.

  • Shengshou Hu, Lingzhi Kong, Runlin Gao, et al. Report On Cardiovascular Diseases In China (2012). Encyclopedia of China Publishing House 2013.

  • He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK. Major causes of death among men and women in China. N Engl J Med. 2005 Sep 15;353(11):1124-34. doi: 10.1056/NEJMsa050467.

    PubMed 16162883
  • Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, Liu J, Cheng J, Bibbins-Domingo K, Shen YM, He J, Goldman L. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):243-52. doi: 10.1161/CIRCOUTCOMES.109.910711. Epub 2010 May 4.

    PubMed 20442213
  • Yang G, Kong L, Zhao W, Wan X, Zhai Y, Chen LC, Koplan JP. Emergence of chronic non-communicable diseases in China. Lancet. 2008 Nov 8;372(9650):1697-705. doi: 10.1016/S0140-6736(08)61366-5. Epub 2008 Oct 17.

    PubMed 18930526
  • Wan YC, Wan YI. Delivering surgical training in the People's Republic of China: are current mechanisms adequate? Int J Surg. 2008 Dec;6(6):443-5. doi: 10.1016/j.ijsu.2008.08.012. Epub 2008 Sep 3.

    PubMed 18838351
  • Grover FL, Shahian DM, Clark RE, Edwards FH. The STS National Database. Ann Thorac Surg. 2014 Jan;97(1 Suppl):S48-54. doi: 10.1016/j.athoracsur.2013.10.015. No abstract available.

    PubMed 24384250
  • Head SJ, Howell NJ, Osnabrugge RL, Bridgewater B, Keogh BE, Kinsman R, Walton P, Gummert JF, Pagano D, Kappetein AP. The European Association for Cardio-Thoracic Surgery (EACTS) database: an introduction. Eur J Cardiothorac Surg. 2013 Sep;44(3):e175-80. doi: 10.1093/ejcts/ezt303. Epub 2013 Jun 19.

    PubMed 23786918
  • Zheng Z, Zhang L, Hu S, Li X, Yuan X, Gao H; Chinese Cardiovascular Surgical Registry Study. Risk factors and in-hospital mortality in Chinese patients undergoing coronary artery bypass grafting: analysis of a large multi-institutional Chinese database. J Thorac Cardiovasc Surg. 2012 Aug;144(2):355-9, 359.e1. doi: 10.1016/j.jtcvs.2011.10.012. Epub 2011 Nov 5.

    PubMed 22056490
  • Hu S, Zheng Z, Yuan X, Wang Y, Normand SL, Ross JS, Krumholz HM. Coronary artery bypass graft: contemporary heart surgery center performance in China. Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):214-21. doi: 10.1161/CIRCOUTCOMES.111.962365. Epub 2012 Mar 6.

    PubMed 22396587
  • Li Y, Zheng Z, Hu S; Chinese Coronary Artery Bypass Grafting Registry Study. The Chinese coronary artery bypass grafting registry study: analysis of the national multicentre database of 9248 patients. Heart. 2009 Jul;95(14):1140-4. doi: 10.1136/hrt.2008.146563. Epub 2008 Jul 16.

    PubMed 18632834
  • Zheng Z, Zhang L, Li X, Hu S; Chinese CABG Registry Study. SinoSCORE: a logistically derived additive prediction model for post-coronary artery bypass grafting in-hospital mortality in a Chinese population. Front Med. 2013 Dec;7(4):477-85. doi: 10.1007/s11684-013-0284-0. Epub 2013 Sep 18.

    PubMed 24048813
  • Zheng Z, Li Y, Zhang S, Hu S; Chinese CABG Registry Study. The Chinese coronary artery bypass grafting registry study: how well does the EuroSCORE predict operative risk for Chinese population? Eur J Cardiothorac Surg. 2009 Jan;35(1):54-8. doi: 10.1016/j.ejcts.2008.08.001. Epub 2008 Sep 7.

    PubMed 18778949
  • Zheng S, Zheng Z, Fan HG, Hu SS; Chinese Cardiovascular Surgery Registry. Is the European System for Cardiac Operative Risk Evaluation useful in Chinese patients undergoing heart valve surgery? Chin Med J (Engl). 2012 Oct;125(20):3624-8.

    PubMed 23075714
  • Ben Bridgewater RK, Jan Gummert, Peter Walton. Fourth EACTS Adult Cardiac Surgical Database Report: Towards Global Benchmarking. Dendrite Clinical Systems Limited 2010.

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Bypass Grafting and Surgical Treatment for Heart Valve Diseases, run by China National Center for Cardiovascular Diseases at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Zhe Zheng, PhD, MD (+861088396356, zhengzhe@fuwai.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

composite of post-operative all-cause mortality and major complications (time frame: participants will be followed for the duration of hospital stay after the index cardiac operation, an expected average of 2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02400125, which also lists 20 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2015.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in